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Vascular smooth muscle cellCyclic AMP signalling promotes VSMC quiescence in healthy vessels and during vascular healing following
injury. Cyclic AMP inhibits VSMC proliferation via mechanisms that are not fully understood. We investigated
the role of PKA and Epac signalling on cAMP-induced inhibition of VSMC proliferation. cAMP-mediated
growth arrest was PKA-dependent. However, selective PKA activation with 6-Benzoyl-cAMP did not inhibit
VSMC proliferation, indicating a requirement for additional pathways. Epac activation using the selective
cAMP analogue 8-CPT-2′-O-Me-cAMP, did not affect levels of hyperphosphorylated Retinoblastoma (Rb)
protein, a marker of G1-S phase transition, or BrdU incorporation, despite activation of the Epac-effector Rap1.
However, 6-Benzoyl-cAMP and 8-CPT-2′-O-Me-cAMP acted synergistically to inhibit Rb-hyperphosphoryla-
tion and BrdU incorporation, indicating that both pathways are required for growth inhibition. Consistent
with this, constitutively active Epac increased Rap1 activity and synergised with 6-Benzoyl-cAMP to inhibit
VSMC proliferation. PKA and Epac synergised to inhibit phosphorylation of ERK and JNK. Induction of stellate
morphology, previously associated with cAMP-mediated growth arrest, was also dependent on activation of
both PKA and Epac. Rap1 inhibition with Rap1GAP or siRNA silencing did not negate forskolin-induced
inhibition of Rb-hyperphosphorylation, BrdU incorporation or stellate morphology. This data demonstrates
for the ﬁrst time that Epac synergises with PKA via a Rap1-independent mechanism tomediate cAMP-induced
growth arrest in VSMC. This work highlights the role of Epac as a major player in cAMP-dependent growth
arrest in VSMC.rsity of Bristol, Level 7 Queens
Tel.: +44 117 3423586.
NC-ND license.© 2010 Elsevier Ltd.Open access under CC BY-NC-ND license.1. Introduction
Vascular smooth muscle cell (VSMC) proliferation contributes
towards intima formation during numerous vasculo-proliferative
diseases, including atherosclerosis, transplant vasculopathy and
pulmonary hypertension. VSMC proliferation also contributes to-
wards neointima formation after balloon angioplasty, with and
without stenting, and after bypass vein grafting, thus limiting the
success of clinical interventions designed to treat atherosclerosis. A
complete understanding of the mechanisms regulating VSMC prolif-
eration during these processes is therefore essential.
In healthy vessels, VSMC exhibit very low rates of proliferation [1].
However, VSMC proliferation rates are dramatically elevated in
response to vessel injury. Mechanisms responsible for this include
release of growth factors and remodelling of the vascular extracellular
matrix [2,3] that activate cell signalling pathways required for cell-cycle
progression.
VSMC proliferation is also subject to negative regulation [4]. cAMP, a
major second messenger produced by adenylate-cyclase has a welldocumented role as an inhibitor of VSMC proliferation. cAMP synthesis
in response to endothelial-derived prostacyclin is an important
mechanismpromotingVSMCquiescence and vascular healing following
injury. For example, elevated cAMP levels have been shown to inhibit
VSMC proliferation in vitro and after vascular injury-induced prolifer-
ation in vivo, ultimately leading to a reduction in restenosis [4,5]. The
mechanisms underlying these growth-inhibitory properties are only
partially understood. Elevated cAMP levels inhibit expression of the G1-
S phase cell-cycle regulators, Cyclin D and Skp2 [4,6], which accounts at
least in part for cAMP-mediated G1-arrest and reduction in neointima
development [7–9]. However, upstream signalling pathways responsi-
ble for these important biological effects of cAMP remain unclear.
At one time, the biological effects of cAMP were thought to be
mediated exclusively by Protein Kinase A (PKA). Consistent with this,
PKA inhibitors have been shown to reverse the effects of cAMP-
elevating agents on VSMC proliferation [5]. However, we recently
reported that cAMP-mediated inhibition of Skp2 expression, a key
regulator of G1-S phase progression, could only be partially reversed by
a PKA inhibitor [4]. Other studies demonstrated PKA-independent
effects of cAMP analogues on cell-cycle regulatory proteins in other cell
types [10,11]. These observations indicate the involvement of additional
PKA-independent cAMP-sensitive pathways involved in cell-cycle
regulation. The recent identiﬁcation of a new family of cAMP-sensitive
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distinct PKA-independent signalling pathway [12–14]. Epac 1 and 2
both contain N-terminal cAMP-binding domains and C-terminal
guanine-nucleotide exchange factor (GEF) domains allowing them to
function as cAMP-binding proteins with intrinsic GEF activity that can
couple cAMP levels to the activation ofmembers of theRas-like family of
GTPases such as Rap1 [12,15]. Numerous highly cell-type speciﬁc
functions for Epac proteins have been proposed, including integrin-
mediated cell adhesion, cell–cell junctions, migration and apoptosis
[16–18] as well as having both pro- and anti-proliferative properties
[19,20], depending on the cell type under investigation. However, the
role of the Epac signalling pathway in cAMP-mediated inhibition of
VSMC proliferation is not known.
Here we show for the ﬁrst time that Epac1 acts synergistically with
PKA to mediate cAMP-dependent cell-cycle arrest and associated
induction of stellate morphology in vascular smooth muscle cells. We
also demonstrate that Epacmediates its effects on cell-cycle arrest in a
Rap1-independent manner.
2. Materials and methods
Male Sprague–Dawley (SD) rats were obtained from Charles River.
Culturemedia and additiveswere obtained from Lonza. Antibodies used
were Skp2 (#32-3400; Zymed Inc.), Rap1, GAPDH (#07-916, #MAB374;
Millipore), Cyclin D1 (#CC12; Calbiochem), Epac (#sc-28366; Santa
Cruz), VASP (#ALX-210-880; Alexis), hyperphosphorylated-Rb, phos-
pho-ERK, ERK, phospho-JNK, JNK (#9308, #9101, #9102,#9251,#9258;
Cell Signalling), V5-tag (#R960-25; Invitrogen), paxillin (#610051; BD
Biosciences), BrdU (#B2531; Sigma) and Rap1GAP (#ab32373; Abcam).
Db-cAMP and forskolin were obtained from Sigma. N6-Benzoyl-cAMP
and 8-CPT-2′-O-Me-cAMP were from Calbiochem. Sp-8-CPT-2′-O-Me-
cAMPS was obtained from Biolog.
2.1. RT PCR
Total RNA was extracted using Qiagen RNease kit (Qiagen),
quantitated using aND1000 nanodrop spectrophotometer and between
100 and 400 ng reverse transcribed using a QuantiTect reverse
transcription kit (Qiagen). Quantitative RT-PCR was performed using
Qiagen QuantiTect SYBR green on a Roche Lightcycler using the
following primers: Epac1 forward 5′-CGACACCACAGGTTGGAGAATG-
3′, Epac1 reverse 5′-AAGCTGCCATCACTTCCCTCAC-3′, Epac2 forward 5′-
TGTGCACGAGCTGGAGCTAATC-3′, Epac2 reverse 5′-TGTACGCCCTGT
GATTTCTGGA-3′, Rap1A forward 5′-AGATTGCCAACAGTGTATGCTGGA-
3′, Rap1A reverse 5′-ATTGCCAACCAAAATCATTGGAAC-3′, Rap1B for-
ward 5′-GATACTGCAGGAACGGAGCAGTTT-3′, Rap1B reverse 5′-
GTCTTGCCAGGTTCTGACCTTGTT-3′, Copy number was calculated by
extrapolation from a standard curve.
2.2. Smooth muscle cell culture and bromo-deoxyuridine labelling
Isolated VSMC were prepared using a modiﬁcation of the explant
technique described previously [1]. Unless otherwise stated, all cells
were cultured in the presence of 10% foetal calf serum and used
between passage 3 and 8. Where indicated, cells were rendered
quiescent by serum deprivation for 72 h. VSMC proliferation was
quantiﬁed by labelling cells with 10 μMBrdU for 6 h, unless otherwise
stated. Cells were ﬁxed and analysed for BrdU incorporation by
immuno-histochemistry with diaminobenzidine staining and counted
using NIH ImageJ software.
2.3. Western blotting
Total cell lysates were prepared using SDS-lysis buffer (50 mM
Tris–HCl, pH 6.8, 10% glycerol, 1% SDS). Protein content was
determined (Micro BCA assay kit, Pierce), and equal amounts ofreduced protein (20–70 μg) were separated by PAGE, transferred to
PVDF membrane, blocked with TBS containing 0.2% Tween and 6%
milk powder before incubation in primary antibody. Speciﬁc proteins
were detected using HRP-conjugated secondary antibodies (Dako, Ely,
UK) and enhanced chemoluminescence. Westerns detecting exoge-
nously expressed proteins were exposed to correctly detect exoge-
nous proteins and thus endogenous expression may not be visible.
2.4. Recombinant adenoviruses and infection of VSMC
Recombinant adenovirus encoding Rap1GAP was a kind gift from
Patrick J. Casey (Duke University Medical Center, North Carolina).
Adenovirus expressing PKA inhibitor was a kind gift from Prof. David
Murphy (University of Bristol, U.K.) [21]. Adenovirus encoding
constitutively active mutant of Epac was constructed by PCR to
amplify the C-terminal GEF domain (aa 322–881) without the N-
terminal DEP and cAMP-binding domains. This cDNA was sub-cloned
with a 5′ V5 tag into the pDC515 adenovirus shuttle vector (Microbix).
Replication-deﬁcient adenoviruses were generated by recombination
of co-transfected shuttle and genomic plasmids in HEK293 cells. Virus
stocks were plaque-puriﬁed, ampliﬁed, CsCl-banded, and titrated by
plaque assay. Asynchronous rat VSMC were infected with adenovirus
at 108 pfu/ml for 16 h, unless otherwise stated.
2.5. Rap1 activity assays
Prokaryotic expression vector for GST-tagged Ral-GDS was a kind
gift from Prof. Peter Cullen (University of Bristol, U.K.). GST-Ral-GDS
protein was puriﬁed from BL21 E. coli on glutathione-sepharose using
standard protocols. VSMC were stimulated as indicated and lysed in
NP-40 lysis buffer (50 mM Tris pH 7.4, 200 mM NaCl, 5 mMMgCl2, 1%
NP-40 alternative, 10% glycerol, 10 μg/ml aprotinin, 10 μg/ml leupep-
tin, 1 mM PMSF). Insoluble material was pelleted by centrifugation at
14,000 rpm and active GTP-bound Rap1 afﬁnity puriﬁed on the GST-
Ral-GDS resin at 4 °C for 45 min with constant mixing. Resin was
washed 6 times in NP-40 lysis buffer and bound Rap1 eluted in SDS-
lysis buffer. Total Rap1 in cell lysates and puriﬁed active Rap1 were
quantiﬁed by western blotting.
2.6. PKA activity assays
PKA activity was assessed using the ﬂuorescent PepTag assay
system (Promega) following the manufacturers protocol, with the
following changes: cells were lysed in buffer containing 25 mM Tris
pH 7.5, 0.5% NP-40 alternative, 1 mM NaF, 1 mM Na-vanadate, 1 mM
PMSF, 10 μg/ml aprotinin, 10 μg/ml leupeptin. Lysates were centri-
fuged without homogenization. PKA activator 5× solution was not
added to sample reaction tubes. PKA phosphorylated peptide gained a
net negative charge and was separated from un-phosphorylated
peptide by electrophoresis on 0.8% agarose gels. Bands were
visualised using a UV transilluminator.
2.7. Phalloidin and paxillin immunoﬂuoresence staining and quantiﬁcation
of focal adhesion area
F-actin was stained with ﬂuorescein-phalloidin (Invitrogen)
following the manufacturers protocol. Brieﬂy, cells were ﬁxed with
4% PFA/PBS, permeabilised with 0.1% Triton/PBS, blocked with 1%
BSA/PBS and labelled with phalloidin. For paxillin staining, cells were
ﬁxed in 4% PFA/PBS, permeabilisedwith 0.1% Triton/PBS, blocked with
20% goat serum, labelled with anti-paxillin and visualised with Alexa
488-conjugated anti-mouse IgG. Coverslips weremounted on slides in
DAPI Vectashield mounting medium (Vector). Mean focal adhesion
areas (typically 90 focal adhesions per condition in each experiment)
in individual cells were manually measured using NIH ImageJ
software.
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VSMCwere transfected in 100 μl with 600 nM of control siRNA (All
Stars negative) or a combination (total of 600 nM) of two siRNAs
targeting Rap1A (Sense 5′-CUGGGAUAACUGAUUUCUATT-3′ and 5′-
UAACGCGGGUUGUCAAUAUUUATT-3′) and two siRNAs targeting
Rap1B (Sense 5′-GCAGAUUCUUCGGGUUAAATT-3′ and 5′-
AGAUAAAUGUUAACGAGAUTT-3′) using the basic smooth muscle
cell electroporation kit (Amaxa). SiRNA-mediated gene silencing was
quantiﬁed 24 h post transfection.
2.9. Statistical analysis
After calculating means and standard errors of the means, analysis
was performed using a two-tailed paired t-test or ANOVA (Student–
Newman–Keuls) as indicated. Signiﬁcant differences were taken
when pb0.05.
3. Results
3.1. Components of the Epac–Rap1pathwayare expressedand functional in
VSMC
We initially sought to determine which components of the Epac–
Rap pathway were expressed by rat aortic vascular smooth muscle
cells. Quantitative reverse transcription PCR for Epac1 and Epac2
mRNA expression demonstrated Epac1 to be the predominant Epac
expressed, being 200 fold higher than Epac2 mRNA levels (Fig. 1A).Fig. 1. The Epac–Rap pathway is expressed and functional in rat VSMC. VSMC were rendered
Epac2, Rap1A and Rap1B mRNA copy number was calculated by quantitative RT-PCR, n=5;
stimulated with 100 μM forskolin for indicated times, and assayed for Rap1 activity by Ral-GD
0 min.Epac1 protein expression was similar in both quiescent and mitogen
stimulated cells (Fig. 1C). We next sought to determine which Rap
isoforms were expressed in VSMC. Since Epac exhibits relatively poor
GEF activity towards Rap2 compared to Rap1 [22], we focused on the
Rap1 isoforms Rap1A and Rap1B, the major GTPases reported to be
activated by Epac. Quantitative RT-PCR detected similar levels of both
Rap1A and Rap1B isoforms in both quiescent and mitogen stimulated
VSMC (Fig. 1B). A pan-Rap1 antibody also detected similar levels of
21 kDa Rap1 protein in quiescent and mitogen stimulated cells
(Fig. 1C). This data demonstrates that rat VSMC express Epac1 and
both isoforms of Rap1. Importantly, stimulation with the adenylate-
cyclase activator forskolin resulted in a signiﬁcant increase in Rap1
activity (Fig. 1D), indicating that the Epac–Rap1 pathway is functional
in VSMC.3.2. Selective activation of PKA and Epac signalling using selective cAMP
analogues
To test the relative contribution of Epac and PKA signalling in the
regulation of VSMC proliferation, we used the PKA-selective cAMP
analogue N6-Benzoyl-cAMP (BNZ) and the Epac-selective cAMP
analogue 8-CPT-2′-O-Me-cAMP (CPT) [23,24]. Stimulation of VSMC
with BNZ but not CPT resulted in a signiﬁcant activation of PKA
activity (6.5±0.75 fold, n=3, pb0.001), measured by kemptide
phosphorylation assay (Fig. 2A). Consistent with this, VSMC stimu-
lation with CPT did not increase phosphorylation of the PKA substrate
VASP (4±1.3% compared to 3.2±1.3% phosphorylated in control)
(Fig. 2B) but did signiﬁcantly activate the Epac target Rap1 (Fig. 2C,quiescent by serum deprivation and stimulated with FCS as indicated: A and B, Epac1,
C, Epac1 and Rap1 protein expression was veriﬁed by western blotting. D, VSMC were
S pulldown, n=6. E, A representative western blot is shown. * indicates pb0.01 versus
Fig. 2. Selective activation of PKA and Epac signalling with N6-Benzoyl-cAMP and 8-CPT-2′-O-Me-cAMP, respectively. VSMC were serum deprived for 24 h and stimulated with
200 μMBNZ, CPT, BNZ plus CPT or 100 μM forskolin for 30 min as indicated. A, Cell lysates were analysed for PKA activity by kemptide phosphorylation assay. Upper bands represent
PKA phosphorylated kemptide while lower bands are un-phosphorylated kemptide. Recombinant PKA catalytic subunit and lysis buffer were included in the assay as positive and
negative controls respectively. B, Cell lysates were analysed for phospho-VASP (slower migrating band) by western blotting with a total VASP antibody, n=3. C, Rap1 activity was
quantiﬁed by Ral-GDS pulldown, n=6. * indicates pb0.05 versus control.
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resulted in a 29.3±16.8% phosphorylation of PKA substrate VASP
(Fig. 2B), without elevating Rap1 activity (Fig. 2C). Co-stimulation
with BNZ plus CPT did not result in additional kemptide or VASP
phosphorylation but did result in a reduced activation of Rap1 that
was no longer signiﬁcantly different from controls (Fig. 2). Elevation
of endogenous cAMP levels with forskolin resulted in 89.8±1.3%
phosphorylation of VASP and a 2.6±0.6 fold activation of Rap1,
indicating an activation of both pathways. This data demonstrated
that PKA and Epac signalling pathways can be selectively activated in
VSMC by BNZ and CPT respectively.
3.3. PKA and Epac synergise to inhibit VSMC proliferation
To investigatewhether activation of PKA alone is sufﬁcient for VSMC
growth arrest, we stimulated VSMC with the PKA-selective analogue
BNZ. Stimulation with BNZ had no effect on BrdU incorporation, Rb-
hyperphosphorylation or the expression levels of Cyclin D or Skp2
(Fig. 3) despite robust PKA activation (Figs. 2A, B and 4C). However,
consistent with previous ﬁndings, stimulation with the non-selective
cAMP analogue dibutyryl-cAMP (db-cAMP) signiﬁcantly inhibited BrdU
incorporation (to 59.3±7.8%of control, n=6, pb0.01) (Fig. 3A) andRb-
hyperphosphorylation (to 29.3±6.5% of control, n=3, pb0.05)
(Fig. 3B). Db-cAMP also inhibited expression of G1-phase cell-cycle
proteins Cyclin D and Skp2 (Fig. 3C). Taken together, these observations
indicate that PKA activity is required but alone insufﬁcient for cAMP-induced growth inhibition in VSMC. Therefore we investigated the role
of the Epac signalling pathway.
Stimulation with the Epac-selective cAMP-analogue CPT alone had
no effect on BrdU incorporation, Rb-hyperphosphorylation or expres-
sion of Cyclin D or Skp2 (Fig. 3) despite robust activation of Rap1
(Fig. 2C). This indicates that Epac activation in isolation is also
insufﬁcient to inhibit VSMC proliferation. Given that elevation of
endogenous cAMP with forskolin or treatment with the non-selective
cAMP analogue db-cAMP induces VSMC growth arrest, we tested the
hypothesis that coordinated activation of both PKA and Epac signalling
is required. Consistent with this, stimulation with both BNZ and CPT
together signiﬁcantly inhibited BrdU incorporation (to 48.3±15.1% of
control, n=6, pb0.001) and Rb-hyperphosphorylation (to 20.3±14.8%
of control, n=3, pb0.05) (Fig. 3). Furthermore, BNZ plus CPT
stimulation potently inhibited expression of Cyclin D and Skp2 to levels
similar to that in db-cAMP treated cells (Fig. 3C). This indicates that
while activation of PKA or Epac alone is insufﬁcient, the simultaneous
activation of both of these cAMP-dependent pathways results in growth
arrest in VSMC.
Given that some reports have demonstrated Epac-independent
effects of CPT metabolites [25,26], we used the non-hydrolysable
derivative of CPT, Sp-8-CPT-2′-O-Me-cAMPS (CPTSp) to conﬁrm that
the effects observed were indeed operating through activation of
Epac. Consistent with our earlier observations (Fig. 3), stimulation of
VSMC with BNZ or CPTSp alone had no effect on BrdU incorporation,
while simultaneous stimulation with both BNZ and CPTSp
Fig. 3. Epac and PKA synergise to inhibit VSMC cell-cycle progression. Asynchronous VSMC
were stimulated with 200 μM BNZ, 200 μM CPT, 200 μM BNZ plus 200 μM CPT, or 200 μM
db-cAMP: A, for 24 hwith the last 6 h in the presence of 10 μMBrdU and analysed for BrdU
incorporation, n=6; B and C, for 18 h and cell lysates analysed by western blotting as
indicated, n=3. * indicates pb0.05, ** indicates pb0.01, *** indicates pb0.001 versus
control.
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(n=6, pb0.05) (Supplemental Fig. 1). The magnitude of growth
inhibition induced by CPTSp plus BNZ was less that that induced by
CPT plus BNZ (Fig. 3B). This probably reﬂects the lower potency of
CPTSp for Epac compared to CPT [27].
To conﬁrm the role of PKA in cAMP-mediated growth arrest,weused
BNZ and PKA inhibitor expressing adenovirus (Ad:PKAI). Infectionwith
Ad:PKAI but not Ad:Control completely inhibited BNZ-stimulated
phosphorylation of VASP, demonstrating potent PKA inhibition in Ad:
PKAI infected cells (Fig. 4A). Forskolin stimulation ofAd:Control infected
cells resulted in dose-dependent and signiﬁcant inhibition of BrdU
incorporation that was prevented by infection with Ad:PKAI (Fig. 4B).
BrdU incorporation in forskolin stimulated Ad:PKAI infected cells was
signiﬁcantly higher (n=7, pb0.05) than in Ad:Control infected cells at
both doses of forskolin tested, demonstrating a requirement for PKA
activity in cAMP-induced growth arrest of VSMC.
Since prolonged PKA activity is necessary for cAMP-mediated VSMC
growth arrest [28], we investigated the effect of Epac stimulation on the
level and duration of BNZ-induced PKA activity. BNZ stimulation alone
caused an induction of PKA activity similar to that caused by forskolin
and lasting at least 16 h (Fig. 4C). Activation of Epac with CPT did not
enhance PKA activity further. This indicates that the synergistic actions
of PKA and Epac occur downstreamof PKA activity, and emphasises that
prolonged PKA activation alone is insufﬁcient for cAMP-mediatedgrowth arrest of VSMC, implying a requirement for an additional cAMP-
sensitive pathway, such as Epac.
To test if Epac activation synergises with PKA to inhibit VSMC
proliferationwe used adenovirus-mediated expression of constitutively
active Epac (Ad:ΔcAMP-Epac) lacking the N-terminal DEP and cAMP-
binding domains. Ad:ΔcAMP-Epac infection resulted in expression of a
~60 kDaΔcAMP-Epac protein and a signiﬁcant 5.8±1.6 fold increase in
Rap1 activity (Fig. 5A), conﬁrming constitutively active GEF activity.
Expression of ΔcAMP-Epac alone did not signiﬁcantly alter BrdU
incorporation or Rb-hyperphosphorylation (Fig. 5), consistent with
our results obtained with CPT. BNZ stimulation of Ad:Control infected
cells had no effect on BrdU incorporation or Rb-hyperphosphorylation
(Fig. 5), consistent with our earlier observation (Fig. 3). However, BNZ
treatment in Ad:ΔcAMP-Epac infected cells induced a signiﬁcant
inhibition of BrdU incorporation (to 39.5±7.7% of Ad:ΔcAMP-Epac
alone, n=4, pb0.01) and Rb-hyperphosphorylation (to 28.1±10.5% of
Ad:ΔcAMP-Epac alone, n=6, pb0.01), further supporting the hypoth-
esis that PKA and Epac signalling synergises to induce VSMC growth
arrest.
3.4. cAMP-dependent growth arrest is Rap1-independent
Since Rap1, the best characterised Epac target protein, was activated
by elevated cAMP levels or expression of constitutively active Epac, we
tested the hypothesis that Epac-dependent activation of Rap1 was
involved in cAMP-induced growth arrest and induction of stellate
morphology in VSMC. We used adenovirus-mediated expression of
Rap1GAP (Ad:Rap1GAP), which speciﬁcally inactivates Rap1 by
increasing GTP hydrolysis [29] and completely inhibited Rap1 activity
in VSMC (Fig. 6A). Ad:Rap1GAP infection resulted in a signiﬁcant
inhibition of basal BrdU incorporation rates (from 38.8±4.0% in Ad:
Control cells to 25.6±4.0% in Rap1GAP infected cells, n=9, p=0.0004)
(Fig. 6B) and Rb-hyperphosphorylation (to 43.5±10.8% of Ad:Control,
n=5, pb0.01) (Fig. 6E), indicative of a pro-proliferative role for Rap1 in
VSMC. Consistent with our earlier observations, forskolin stimulation of
Ad:Control infected cells resulted in a signiﬁcant and dose-dependent
inhibition of BrdU incorporation (pb0.01 for all forskolin doses tested)
(Fig. 6C) and Rb-hyperphosphorylation (65.0±12.1% inhibition for
100 μM forskolin, n=5, pb0.001) (Fig. 6E). Importantly, inhibition of
Rap1 activity with Ad:Rap1GAP did not prevent forskolin-induced
arrest. Forskolin stimulation still resulted in a signiﬁcant inhibition of
BrdU incorporation (pb0.05 for all forskolin doses tested at both Ad:
Rap1GAP doses) themagnitude of whichwas not signiﬁcantly different
from that of Ad:Control infected cells at any dose of forskolin tested.
Furthermore, forskolin stimulation resulted in a signiﬁcant inhibition of
Rb-hyperphosphorylation in Ad:Rap1GAP cells (94.9±2.4% and 94.6±
2.2% inhibition compared to Ad:Rap1GAP alone for 25 and 100 μM
forskolin respectively, n=5, pb0.05) thatwasnot smaller inmagnitude
than that in Ad:Control infected cells. In fact, Rap1 inhibition resulted in
a signiﬁcantly larger inhibition of Rb-hyperphosphorylation in response
to 25 μM forskolin compared to Ad:Control cells (94.9±2.4% versus
37.8±20.6%, n=5, pb0.05), consistent with a pro-proliferative, rather
than an anti-proliferative, role for Rap1 in VSMC. Rap1 inhibition with
Ad:Rap1GAP also had no effect on the magnitude of growth inhibition
induced by a combination of BNZ plus CPT (59.1±9.5% inhibition and
59.3±19.2% inhibition in Ad:Control and Ad:Rap1GAP infected cells
respectively).
To further conﬁrm theRap1-independence of cAMP-induced growth
arrest in VSMC, we used siRNA to speciﬁcally silence expression of both
Rap1A and Rap1B isoforms. Co-transfection with siRNA targeting both
Rap1AandRap1B resulted in a signiﬁcant inhibition of Rap1AandRap1B
mRNA expression (82.0±3.3% silencing for Rap1A and 83.4±3.2%
silencing for Rap1B, n=4, pb0.05) but not GAPDH mRNA expression,
compared to control siRNA transfected cells (Fig. 6F). Rap1-siRNA also
signiﬁcantly inhibited expression of Rap1 protein detected with a pan-
Rap1A/B antibody (51.1±11.4% inhibition, n=3, pb0.05) but did not
Fig. 4. PKA is required but not sufﬁcient to inhibit VSMC cell-cycle progression. VSMC were infected with either Ad:Control or Ad:PKAI at 2×108 pfu/ml. A, 40 h later, cells were
rendered quiescent by serum deprivation for a further 6 h followed by stimulation with 200 μM BNZ for 15 min. Total cell lysates were analysed for non-phosphorylated (lower
band) and phosphorylated (upper band) VASP by western blotting, n=3. B, Asynchronous VSMC were stimulated with forskolin for 24 h with the last 6 h in the presence of 10 μM
BrdU. BrdU incorporation was quantiﬁed by immuno-staining for BrdU and counting of positively stained nuclei, n=7. C, Asynchronous VSMC were stimulated for the indicated
times with 200 μM BNZ, 200uM CPT, 200 μM BNZ plus 200 μM CPT, or 100 μM forskolin, and analysed for PKA activity by kemptide phosphorylation assay. Upper bands represent
PKA phosphorylated kemptide while lower bands are un-phosphorylated kemptide. Recombinant PKA catalytic subunit and lysis buffer were included in the assay as positive and
negative controls respectively. * indicates pb0.05, ** indicates pb0.01 versus Ad:Control alone. # indicates pb0.05 versus corresponding dose in Ad:Control.
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signiﬁcant inhibition of basal proliferation rates (from 46.4±3.4% to
38.5±1.2%, n=3, pb0.05), consistent with our data obtained with
Rap1GAP (Fig. 6G). However, silencing of Rap1 did not result in reversal
of forskolin-induced growth arrest. Taken together, this data demon-
strates that cAMP-mediated growth arrest and induction of stellate
morphology occurs via a Rap1-independent mechanism in VSMC.3.5. PKA and Epac synergise to inhibit ERK and JNK signalling
Some reports suggest that the growth-inhibitory effects of cAMP
can be mediated through inhibition of ERK signalling [30–32]. In
addition, the reported regulation of JNK by Epac, independent of its
GEF activity [33], represents a Rap1-independent mechanism for Epac
signalling. In order to elucidate the role of ERK and JNK in cAMP-
Fig. 5. Constitutively active Epac synergises with PKA to inhibit VSMC cell-cycle progression. Asynchronous VSMC were infected with an adenovirus encoding ΔcAMP-Epac as indicated.
A, Rap1 activity in expressing and non-expressing cells was detected by Ral-GDS pulldown, n=4. Cells were stimulated with 200 μM BNZ: B, for 24 h with the last 6 h in the presence of
10 μM BrdU and analysed for BrdU incorporation, n=4; C, for 18 h and cell lysates were analysed by western blotting for Rb-hyperphosphorylation, n=6. ** indicates pb0.01 versus
Ad:ΔcAMP-Epac.
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phosphorylation states in mitogen stimulated VSMC. Elevation of
endogenous cAMP with forskolin, which results in activation of both
PKA and Epac (Fig. 2), inhibited both ERK1/2 and JNK phosphorylation
induced by acute serum stimulation (Figs. 7A and B). Inhibition of JNK
phosphorylation was only evident at late (1–4 h) but not early (15–
30 min) time points (Fig. 7B). Forskolin also inhibited ERK1/2 but not
JNK phosphorylation in cells grown continuously in the presence of
serum (Figs. 7C and D). To determine the relative contribution of PKA
and Epac to this inhibition of ERK1/2 and JNK signalling, we treated
serum deprived cells with BNZ, CPT or BNZ plus CPT before 2% serum
stimulation (in the continued presence of the indicated cAMP
analogues) for two hours. BNZ or CPT alone had no signiﬁcant effect
on ERK1/2 or JNK phosphorylation (Figs. 7E and F). However,
stimulation with both BNZ and CPT together signiﬁcantly inhibited
ERK1/2 and JNK phosphorylation, indicating that PKA and Epac
synergise to inhibit these kinases (Figs. 7E and F).
3.6. PKA and Epac synergise to induce stellate morphology and associated
actin cytoskeleton and focal adhesion disruption in a Rap1-independent
manner
Our previous observations demonstrated that cAMP-mediated
growth arrest of VSMC is associated with induction of stellatemorphology, characterised by loss of actin stress ﬁbres and focal
adhesions, both of which are essential for cell-cycle progression [34,35].
We therefore tested the hypothesis that activation of PKA and Epac
signalling is associated with a synergistic induction of stellate
morphology and cytoskeleton disruption. Consistent with this, BNZ or
CPT stimulation alone did not result in induction of stellatemorphology.
These cells retained prominent actin stress ﬁbres and there was no
signiﬁcant effect on focal adhesion area (Fig. 8). Importantly, co-
stimulation with BNZ plus CPT induced a pronounced stellate
morphology (Fig. 8A) associated with loss of actin stress ﬁbres
(Fig. 8B) and a signiﬁcant decrease in focal adhesion area (Fig. 8D).
Furthermore, VSMC infectedwith Ad:Rap1GAP or Ad:Control adopted a
similar stellate morphology in response to forskolin stimulation, with
associated loss of actin stress ﬁbres and focal adhesions (Supplemental
Fig. 2), indicating that these effects are not mediated by Rap1. This
coordinated induction of stellate morphology represents a potential
downstream mechanism by which the synergy between PKA and Epac
signalling (independent of Rap1) may mediate cAMP-induced VSMC
growth arrest.
4. Discussion
cAMP is a major second messenger involved in the regulation of
VSMC proliferation. The ability of vascular cells to synthesise cAMP is
Fig. 6. Inhibition of Rap1 does not negate the effects of cAMP on cell-cycle progression. Where indicated, asynchronous VSMCwere infected with an adenovirus encoding Rap1GAP at
108 pfu/ml (high) or 2×107 pfu/ml (low) (A–E), or transfected with siRNA speciﬁc for Rap1 as described (F, G). High dose of Ad:Rap1GAPwas used unless otherwise indicated. VSMC
were stimulated with the indicated forskolin doses for 18 h. A, Rap1GAP activity was conﬁrmed by Rap1 activity assay. B, VSMCwere incubated for 6 h in the presence of 10 μMBrdU
and analysed for BrdU incorporation, n=9. C, VSMC were stimulated with the forskolin doses indicated for a further 6 h in the presence of 10 μM BrdU and analysed for BrdU
incorporation, n=3; D and E, cell lysates were analysed by western blotting as indicated, n=5. F, 24 h post transfection, mRNA levels of Rap1A and Rap1B were quantiﬁed by RT-
PCR, n=4; F (inset), and cell lysates were analysed bywestern blotting with a pan-Rap1A/B antibody; G, VSMCwere stimulated with the indicated forskolin doses a further 6 h in the
presence of 10 μMBrdU and analysed for BrdU incorporation, n=6. * indicates pb0.05 versus siCtrl. ** indicates pb0.01, *** indicates pb0.001 versus Ad:Control. # indicates pb0.05,
## indicates pb0.01 versus Ad:Rap1GAP.
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VSMC quiescence. Reduced synthesis of cAMP after vessel injury is
likely to be an important mechanism in removing the “brake” on
proliferation. In this study, we show for the ﬁrst time that PKA and
Epac act synergistically to induce growth arrest in VSMC via a Rap1-
independent mechanism.
The growth-inhibitory properties of cAMP in VSMC have been
recognised for many years [5]. Elevated cAMP levels arrest cells in G1
phase of the cell cycle, at least in part through inhibition of G1-
regulatory proteins Cyclin D1 and Skp2 [4,6]. However, upstream
signalling mechanisms underlying these anti-proliferative effects have
remained elusive. Several studies demonstrated a clear role for PKA, at a
time when this was the only known cAMP-sensitive protein. ForFig. 7. Epac and PKA synergise to inhibit phosphorylation of ERK1/2 and JNK. A and B, Effec
rendered quiescent by serum deprivation for 24 h and pre-treated with 25 μM forskolin as in
for the timepoints (minutes) indicated. C and D, Effect of forskolin on ERK1/2 and JNK phosp
with 25 μM forskolin in the presence of 10% serum for the timepoints (minutes) indicated. E
JNK phosphorylation. VSMC were rendered quiescent for 24 h and pre-treated with 200
timepoints (minutes). Levels of phosphorylated and total ERK1/2 and JNKwere quantiﬁed by
logged data.example, PKA inhibition completely reversed cAMP inhibition of VSMC
proliferation and injury-inducedneointima formation in vivo [5] andour
results are consistent with this essential role of PKA in cAMP-mediated
growth arrest. Our data now demonstrates that PKA activation is
essential for cAMP-mediated growth arrest but alone is unable to induce
these effects, indicating a requirement for an additional cAMP-sensitive
pathway. The recent identiﬁcation of the Epac family of cAMP-sensitive
GEFs demonstrated the existence of a distinct signalling pathway
directly activated by cAMP [12]. Characterisation of Epac proteins in
different cell types shows diverse andhighly cell-type speciﬁc functions,
reﬂecting the speciﬁc effects of cAMP in those cells. These include
integrin-dependent adhesion, cell–cell junction formation, apoptosis,
cardiac hypertrophy, cell differentiation, cytoskeleton rearrangements,t of forskolin on acute serum stimulated ERK1/2 and JNK phosphorylation. VSMC were
dicated for 30 min before stimulation with 10% serum in the presence of 25 μM forskolin
horylation in cells grown continuously in the presence of serum. VSMC were stimulated
and F, Effect of PKA and Epac-selective analogues on acute serum stimulated ERK1/2 and
μM of the indicated cAMP analogues before 2% serum stimulation for the indicated
western blotting. * indicates pb0.05; ANOVAwith Student–Newman–Keuls post test on
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Fig. 8. Epac and PKA synergise to induce stellate morphology. Asynchronous VSMC were stimulated with 200 μM BNZ, CPT or BNZ plus CPT as indicated. A, Phase contrast images
showing cell morphology. B, Phalloidin staining for F-actin. C, Paxillin staining representing focal adhesions, D, the area of which was quantiﬁed using NIH ImageJ, n=3. * indicates
pb0.05 versus control.
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Epac signalling in cAMP-mediated growth arrest of VSMC remained
unknown. We show that Epac1 but not Epac2 is expressed in VSMC
together with the Epac-effector proteins Rap1A and Rap1B. Further-
more, we show that Rap1 is activated in response to forskolin or by an
Epac-selective cAMP analogue, demonstrating that this pathway is
present and functional in VSMC. The development of cAMP analogues,
selective for PKA or Epac [23], has provided invaluable tools for the
analysis of PKA and Epac signalling and we conﬁrm their speciﬁcity in
VSMC. Using these analogues, we show for the ﬁrst time that activation
of either pathway alone had little effect on proliferation, while dual
activation potently suppressed it. This indicates that Epac plays a major
role, in synergy with PKA, in mediating cAMP-dependent growth
inhibition of VSMC. This novel function for Epac in VSMCwas conﬁrmed
using adenovirus-mediated expression of a constitutively activated
truncation of Epac. Activation of Epac in this way, independent of PKA
stimulation, had no effect of cell proliferation. However, co-stimulation
of PKApotently suppressed proliferation andRb-hyperphosphorylation,
again demonstrating a synergistic interaction between PKA and Epac
signalling in mediating VSMC growth arrest. In order to further conﬁrm
the role of Epac in cAMP-mediated growth inhibition in VSMC, we
employed siRNA-mediated gene silencing (data not shown). Interest-
ingly, Epac siRNA failed to reverse forskolin-induced growth arrest
despite efﬁcient silencing of Epac protein expression. However, great
care must be taken when interpreting data from Epac silencing
experiments since Epac is known to control both cAMP-dependent
and cAMP-independent signalling pathways [33]. This considered, Epac
silencing does not equate to inhibition of Epac activity. For example,
Epac has recently been shown to control JNK signalling in a cAMP-
independent manner [33] and consistent with this, we ﬁnd that Epac
silencing also inhibits JNK activity in VSMC (data not shown). These
cAMP-independent functions of Epac complicate analysis of Epacsilencing data and probably explain the inability of Epac silencing to
reverse cAMP-mediated growth arrest. Future development of speciﬁc
pharmacological Epac antagonists should facilitate this type of func-
tional analysis of Epac and allow both in vitro and in vivo conﬁrmation of
the role of Epac in VSMC growth regulation.
Co-operation or synergy between PKA and Epac has been recently
reported in PCCL3 thyroid cell line in which cAMP is pro-mitogenic, in
contrast to VSMC [19]. Our study demonstrates for the ﬁrst time that
PKA and Epac also synergise to inhibit cell proliferation in a cell type
where cAMP in anti-mitogenic. However, other studies have indicated
both pro- [36] and anti-proliferative [20] properties of Epac signalling
independent of PKA, highlighting the complex and highly cell-type
speciﬁc nature of this signalling network.
There is evidence that the growth-inhibitory effect of cAMP in VSMC
is dependent on theprolonged rather than transient PKAactivation [28].
However, our data demonstrates that stimulation with a PKA-selective
cAMP analogue fails to induce growth arrest, despite inducing robust
PKA activation that persists for at least 16 h and is actually greater than
that induced by forskolin at later time points. Furthermore, we show
that Epac activation did not further increase PKA activity. This data
indicates that synergy between PKA and Epac signalling does not occur
at the level of PKA activation.
Several studies have demonstrated a role for Epac signalling in the
activation of Rap1, with an additional role for PKA signalling [12,37,38].
This suggests that Rap1may act as a common target for PKA and Epac in
some cell types, raising the possibility of synergy between PKA and Epac
acting at the level of Rap1 activation. However, our data demonstrates
that PKA signalling did not enhance Epac-dependent Rap1 activation in
VSMC but instead decreased it, indicating that PKA actually antagonised
Epac-dependent Rap1 activation. Rap1 activation is therefore an
unlikely target for the synergy between these two pathways. In
accordance with this, speciﬁc and complete inhibition of Rap1 activity
97R.C. Hewer et al. / Journal of Molecular and Cellular Cardiology 50 (2011) 87–98with Rap1GAP did not reverse the effects of cAMP-elevation on cell
proliferation, demonstrating that cAMP-dependent growth inhibition is
Rap1-independent inVSMC. Rap1-independencewas further conﬁrmed
using siRNA-mediated silencing of Rap1 A/B. This clearly implicates a
role for other currently unidentiﬁed Epac-effector proteins in cAMP-
dependent growth arrest. Althoughmany studies demonstrate a role for
Rap1 signalling in mediating the effects of Epac activation in other cell
types [18], several studies have alsodescribedRap1-independent effects
of Epac, similar to those described in this study [33,39]. Future research,
beyond the scope of the current study, should focus on identifying and
characterising other Epac-effector proteins to advance our understand-
ing of the mechanisms underlying cAMP-dependent signalling. Taken
together, this data indicates that the synergy between PKA and Epac
signallingmust occur at a level further downstream and not at the level
of PKA or Epac activity itself.
The level at which PKA and Epac pathways synergise remains
unclear. One plausible mechanistic model is that PKA and Epac
independently target different, redundant downstream cell-cycle
regulators, such as the G1-phase regulatory proteins Cyclin D and
Skp2. In this model, growth inhibition would only occur when
expression of both cell-cycle regulators were suppressed by the
simultaneous activation of both pathways. However, expression of
Cyclin D and Skp2, known targets of cAMP signalling, is not affected by
PKA or Epac signalling in isolation but potently suppressed when both
are activated together. This suggests that PKA and Epac synergise
upstream of G1 regulatory proteins.
Our data also clearly demonstrates that cAMP-induced stellate
morphology in VSMC, with the associated loss of actin stress ﬁbres
and focal adhesions, is dependent upon activation of both PKA and
Epac signalling suggesting that synergy may occur at the level of
cytoskeleton organisation. Both PKA and Epac have been previously
implicated in cytoskeleton regulation in other cell types by targeting
numerous downstream proteins involved in the regulation of actin-
polymerisation, including VASP, RhoA, Rac1 and Merlin [18,40–42].
cAMP-dependent growth inhibition in VSMC is associated with this
induction of stellate morphology and loss of cytoskeleton integrity
suggesting a possible causative role. Numerous studies have demon-
strated a critical requirement forcytoskeleton integrity and organisa-
tion for G1-S phase progression [34,43], suggesting that the
cytoskeleton may act as a nexus for PKA and Epac-dependent signals,
ultimately controlling VSMC proliferation.
It remains to be determined whether cytoskeleton remodelling
represents the primary mechanism for cAMP-dependent growth
arrest in VSMC. However, several studies have demonstrated that
mitogenic signalling through the ERK1/2 pathway is dependent on
cytoskeleton integrity. We investigated whether inhibition of mem-
bers of the MAPK pathway could be a target for synergy between PKA
and Epac signalling since they have been implicated in cAMP-
mediated growth arrest in some cell types [24,44], but not others
[45,46]. For example, Epac signalling has been reported to regulate
JNK signalling in HEK-293T cells while elevated cAMP has also been
shown to inhibit ERK activation [24,33]. Whether cAMP inhibits VSMC
proliferation via ERK1/2 in VSMC remains controversial [44,45].
However, elevation of endogenous cAMP with forskolin in our
experiments resulted in inhibition of both basal and serum stimulated
ERK and JNK phosphorylation. CPT and BNZ stimulation synergised to
inhibit ERK and JNK phosphorylation, indicating that coordinated
signalling of PKA and Epac mediates inhibition of these MAPKs and
may contribute to the anti-proliferative effects of cAMP in VSMC.
The requirement for two distinct signalling pathways for cAMP-
induced growth arrest likely represents an important mechanism
allowing VSMC to ﬁnely modulate their cellular responses to cAMP-
elevating stimuli. Our data demonstrates for the ﬁrst time that
activation of both pathways in VSMC results in potent and synergistic
growth arrest and these observations highlight Epac alongside PKA as
amajor player in cAMP-dependent growth arrest in VSMC in vitro. Thefuture development of Epac-speciﬁc pharmacological antagonists and
analysis of Epac-deﬁcient mice will allow validation of the relative
roles of PKA and Epac in the regulation of VSMC proliferation during
the development of vascular disease in vivo.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.yjmcc.2010.10.010.
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